Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Nurix Therapeutics, Inc. (NASDAQ:NRIX) with a price target ...

Marc Frahm, an analyst at TD Cowen, downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) from Buy to Hold. This ...

Morgan Stanley analyst Sarita Kapila resumed coverage of Sanofi (NASDAQ:SNY), assigning an Equal Weight rating and setting a $56 price target.

A French pharmaceutical giant is acquiring a Cambridge, Mass. biotech and its rare immunology disease treatment which is ...

We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where ...

China added fuel to simmering trade tensions with the US, setting investors on guard as they turned the page on a bullish May ...

Since joining Ardelyx in March 2024, Mr. Kelliher has established himself as important leader driving Ardelyx's long-term growth and value creation strategies. In his newly expanded role as Chief ...

Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out ...

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a ...

Shares of Blueprint Medicines Corp (NASDAQ:BPMC) surged 26.5% following the announcement that the biopharmaceutical company will be acquired by Sanofi (NASDAQ:SNY) in a deal valued at approximately $9 ...

US stock futures fell as investors reviewed the latest tariffs news, including China's accusations against the U.S. and ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Blueprint Medicines Corporation to Sanofi is fair to Blueprint shareholders. Under the terms of the proposed ...